Eli Lilly & Co. Price Target Lowered to $54.00 at Goldman Sachs Group Inc. (LLY)
Stock analysts at Goldman Sachs Group Inc. reduced their target price on shares of Eli Lilly & Co. (NYSE:LLY) to $54.00 in a report issued on Thursday, AnalystRatingsNetwork.com reports. Goldman Sachs Group Inc.’s price target points to a potential upside of 2.64% from the company’s current price.
Shares of Eli Lilly & Co. (NYSE:LLY) traded down 4.52% on Thursday, hitting $50.23. 7,931,085 shares of the company’s stock traded hands. Eli Lilly & Co. has a 52 week low of $44.88 and a 52 week high of $58.40. The stock’s 50-day moving average is $52.91 and its 200-day moving average is $53.64. The company has a market cap of $54.258 billion and a price-to-earnings ratio of 11.82.
Eli Lilly & Co. (NYSE:LLY) last released its earnings data on Wednesday, July 24th. The company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.15. The company had revenue of $5.93 billion for the quarter, compared to the consensus estimate of $5.82 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Analysts expect that Eli Lilly & Co. will post $4.14 EPS for the current fiscal year.
A number of other firms have also recently commented on LLY. Analysts at Sanford C. Bernstein reiterated a “buy” rating on shares of Eli Lilly & Co. (NYSE:LLY) in a research note to investors on Tuesday. They now have a $61.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Eli Lilly & Co. (NYSE:LLY) from $59.00 to $61.00 in a research note to investors on Tuesday. They now have a “neutral” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Eli Lilly & Co. (NYSE:LLY) in a research note to investors on Tuesday, September 3rd. They now have a $54.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. Eli Lilly & Co. has a consensus rating of “Hold” and an average price target of $57.33.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.